Trials / Completed
CompletedNCT01323959
Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults
Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 212 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 25 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the persistence of immune response against diphtheria, tetanus, pertussis and poliomyelitis in healthy adults, 10 years after a booster dose, and also assess the immunogenicity and safety of another booster dose of BoostrixTM Polio.
Detailed description
This protocol posting has been updated following protocol amendment 1, dated 03 June 2011. The impacted section is: Eligibility Criteria (Exclusion criteria).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BoostrixTM Polio | Single dose, intramuscular administration. |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2011-03-28
- Last updated
- 2018-06-06
- Results posted
- 2017-08-03
Locations
15 sites across 2 countries: France, Germany
Source: ClinicalTrials.gov record NCT01323959. Inclusion in this directory is not an endorsement.